Apyx Medical Corporation

APYX Healthcare Medical Devices

Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.

2.55 0.01 −0.39%
Market cap
$107.8M
P/E
0.0×
Fwd P/E
−16.0×
Dividend yield
—
F-score
4/9
Altman Z
1.10
Beneish M
−2.63
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 5 4 4

+8 more TTM periods

ROE
(93.11%) (77.27%) (76.88%) (168.32%)
ROA
(14.48%) (14.89%) (17.03%) (24.63%)
ROIC
(11.76%) (15.79%) (22.44%) (38.15%)
Return on Tangible Assets
(18.81%) (19.27%) (22.81%) (36.17%)
Average Days of Receivables
85.07 83.28 115.87 99.02
Free Cash Flow per Share
(0.25) (0.21) (0.22) (0.23)
Free Cash Flow
(11.05) (8.99) (9.11) (9.49)
Capital Expenditures
(0.92) (1.12) (1.11) (1.08)
Other line items
Cash ROIC
(14.92%) (11.33%) (11.19%) (14.42%)
Accounts Receivable Turnover
4.70 4.58 3.28 3.68
Accounts Payable Turnover
8.39 8.35 6.98 6.97
Inventory Turnover
2.25 2.39 2.45 1.97
Average Days of Payables
37.49 46.58 56.37 65.68
Days of Inventory on Hand
183.95 168.96 158.57 186.55
Tax Rate
0.06 0.04 0.02 0.02
Research and Development Expense of Revenue
5.65% 5.96% 6.38% 7.40%
Selling, General and Administrative Expense of Revenue
63.90% 64.89% 68.35% 75.09%
Share Based Compensation of Revenue
4.14% 3.33% 3.79% 4.88%
Interest Coverage
(0.63) (0.77) (1.15) (1.63)
Operating CF/Net income
1.17 0.86 0.71 0.58
Depreciation/Fixed assets
0.37 0.32 0.28 0.24
Capex/Depreciation
(1.17) (1.56) (1.70) (1.88)
Revenue per Share
1.33 1.28 1.29 1.18
Operating CF per Share
(0.23) (0.18) (0.19) (0.21)
Capex per Share
(0.02) (0.03) (0.03) (0.03)
Capex to Sales
0.02 0.02 0.02 0.02

Fold the line items

Columns are period end dates